Study findings suggest using the drug PF-06409577 to restore CDX2 in colon cancers could cut risk of recurrence and death by up to 50%.

BioAgilytix now operates 355,000-square-feet of laboratory facilities, including 24,000-square-feet dedicated to LC/MS.

Genomics unveils Mystra at ASHG 2025—an AI genetics platform to accelerate drug discovery and clinical validation using large-scale genetic data.